ArticleThe Journal of biological chemistry2012
Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells.
Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 77 citations in OpenAlex.
- MiRNA-132/212 encapsulated by adipose tissue-derived exosomes worsen atherosclerosis progression.Cardiovascular diabetology · 2024Article
- The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Discovery and Validation of Circulating microRNAs as Biomarkers for Epileptogenesis after Experimental Traumatic Brain Injury-The EPITARGET Cohort.International journal of molecular sciences · 2023Article
- Placental microRNA methylome signatures may serve as biomarkers and therapeutic targets for prenatally opioid-exposed infants with neonatal opioid withdrawal syndrome.Frontiers in genetics · 2023Article
- Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease.JACC. Basic to translational science · 2022Review
- Circular RNAs: regulators of vascular smooth muscle cells in cardiovascular diseases.Journal of molecular medicine (Berlin, Germany) · 2022Review
- miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.Molecular therapy. Nucleic acids · 2022Review
- Article
- Angiotensin II-Induced Long Non-Coding RNACells · 2021Article
- Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan.Biomedicines · 2021Article
- Therapeutic Biomaterial Approaches to Alleviate Chronic Limb Threatening Ischemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Heal the heart through gut (hormone) ghrelin: a potential player to combat heart failure.Heart failure reviews · 2021Review
- miR-132/212 Impairs Cardiomyocytes Contractility in the Failing Heart by Suppressing SERCA2a.Frontiers in cardiovascular medicine · 2021Article
- Advances in miR-132-Based Biomarker and Therapeutic Potential in the Cardiovascular System.Frontiers in pharmacology · 2021Review
- Role of RASA1 in cancer: A review and update (Review).Oncology reports · 2020Review
- Embryonic gene expression altered by maternal exposure to air pollution in rats.Environmental science and pollution research international · 2020Article
- ACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspects.Neuromolecular medicine · 2020Review
- MicroRNA-132 regulates salt-dependent steady-state renin levels in mice.Communications biology · 2020Article
- Article
- PTEN (Phosphatase and Tensin Homolog) Protects Against Ang II (Angiotensin II)-Induced Pathological Vascular Fibrosis and Remodeling-Brief Report.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Angiotensin II (Ang II)-mediated vascular smooth muscle cell dysfunction plays a critical role in cardiovascular diseases. However, the role of microRNAs (miRNAs) in this process is unclear. We used small RNA deep sequencing to profile Ang II-regulated miRNAs in rat vascular smooth muscle cells (VSMC) and evaluated their role in VSMC dysfunction. Sequencing results revealed several Ang II-responsive miRNAs, and bioinformatics analysis showed that their predicted targets can modulate biological processes relevant to cardiovascular diseases. Further studies with the most highly induced miR-132 and miR-212 cluster (miR-132/212) showed time- and dose-dependent up-regulation of miR-132/212 by Ang II through the Ang II Type 1 receptor. We identified phosphatase and tensin homolog (PTEN) as a novel target of miR-132 and demonstrated that miR-132 induces monocyte chemoattractant protein-1 at least in part via PTEN repression in rat VSMC. Moreover, miR-132 overexpression enhanced cyclic AMP-response element-binding protein (CREB) phosphorylation via RASA1 (p120 Ras GTPase-activating protein 1) down-regulation, whereas miR-132 inhibition attenuated Ang II-induced CREB activation. Furthermore, miR-132 up-regulation by Ang II required CREB activation, demonstrating a positive feedback loop. Notably, aortas from Ang II-infused mice displayed similar up-regulation of miR-132/212 and monocyte chemoattractant protein-1, supporting in vivo relevance. In addition, microarray analysis and reverse transcriptase-quantitative PCR validation revealed additional novel miR-132 targets among Ang II-down-regulated genes implicated in cell cycle, motility, and cardiovascular functions. These results suggest that miR132/212 can serve as a novel cellular node to fine-tune and amplify Ang II actions in VSMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.